Literature DB >> 33777918

Is Malaysia Ready for Human Gene Editing: A Regulatory, Biosafety and Biosecurity Perspective.

V Kalidasan1, Kumitaa Theva Das1.   

Abstract

Gene editing platforms have revolutionized the field of genetics with a direct impact on the public health system. Although there are apparent benefits, it is often accompanied by public debates over its uncertainties and risks. In the Malaysian context, modern biotechnology has raised questions about how to best govern gene editing in regulations, biosafety, and biosecurity. Even though standards and guidelines on stem cell and cell-based therapies have been developed, there are no appropriate legal frameworks available for gene editing yet. Nevertheless, biosafety regulations were established to balance promoting biotechnology and protecting against their potential environmental and human health risks. There is also a need to address the potential of genetically modified organisms (GMOs) as bioweapons. Numerous frameworks from several international organizations may provide valuable input in formulating documents on gene editing. By establishing comprehensive guidelines, legal policies, and standards to tackle the challenges and risks associated with gene editing, Malaysia can successfully apply this modern technology in this country.
Copyright © 2021 Kalidasan and Theva Das.

Entities:  

Keywords:  CRISPR; Malaysia; biosafety; biosecurity; gene editing; gene therapy; regulation

Year:  2021        PMID: 33777918      PMCID: PMC7992004          DOI: 10.3389/fbioe.2021.649203

Source DB:  PubMed          Journal:  Front Bioeng Biotechnol        ISSN: 2296-4185


  47 in total

Review 1.  Human Germline Genome Editing.

Authors:  Kelly E Ormond; Douglas P Mortlock; Derek T Scholes; Yvonne Bombard; Lawrence C Brody; W Andrew Faucett; Nanibaa' A Garrison; Laura Hercher; Rosario Isasi; Anna Middleton; Kiran Musunuru; Daniel Shriner; Alice Virani; Caroline E Young
Journal:  Am J Hum Genet       Date:  2017-08-03       Impact factor: 11.025

2.  Gene therapy. As Gelsinger case ends, gene therapy suffers another blow.

Authors:  Jennifer Couzin; Jocelyn Kaiser
Journal:  Science       Date:  2005-02-18       Impact factor: 47.728

Review 3.  Regulation of Stem Cell Technology in Malaysia: Current Status and Recommendations.

Authors:  Nishakanthi Gopalan; Siti Nurani Mohd Nor; Mohd Salim Mohamed
Journal:  Sci Eng Ethics       Date:  2019-05-23       Impact factor: 3.525

4.  CRISPR-baby scientist fails to satisfy critics.

Authors:  David Cyranoski
Journal:  Nature       Date:  2018-12       Impact factor: 49.962

5.  Genome engineering: the next genomic revolution.

Authors:  Charles A Gersbach
Journal:  Nat Methods       Date:  2014-10       Impact factor: 28.547

6.  China delivers verdict on gene editing of babies.

Authors:  Jon Cohen; Dennis Normille
Journal:  Science       Date:  2020-01-10       Impact factor: 47.728

Review 7.  Experiences in Engaging the Public on Biotechnology Advances and Regulation.

Authors:  M Megan Quinlan; Joe Smith; Raymond Layton; Paul Keese; Ma Lorelie U Agbagala; Merle B Palacpac; Louise Ball
Journal:  Front Bioeng Biotechnol       Date:  2016-02-02

8.  Regulatory Considerations for Gene Therapy Products in the US, EU, and Japan.

Authors:  Celine-Lea Halioua-Haubold; James G Peyer; James A Smith; Zeeshaan Arshad; Matthew Scholz; David A Brindley; Robert E MacLaren
Journal:  Yale J Biol Med       Date:  2017-12-19

Review 9.  Therapeutic gene editing: delivery and regulatory perspectives.

Authors:  Gayong Shim; Dongyoon Kim; Gyu Thae Park; Hyerim Jin; Soo-Kyung Suh; Yu-Kyoung Oh
Journal:  Acta Pharmacol Sin       Date:  2017-04-10       Impact factor: 6.150

10.  Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic.

Authors:  Dianne Nicol; Lisa Eckstein; Michael Morrison; Jacob S Sherkow; Margaret Otlowski; Tess Whitton; Tania Bubela; Kathryn P Burdon; Don Chalmers; Sarah Chan; Jac Charlesworth; Christine Critchley; Merlin Crossley; Sheryl de Lacey; Joanne L Dickinson; Alex W Hewitt; Joanne Kamens; Kazuto Kato; Erika Kleiderman; Satoshi Kodama; John Liddicoat; David A Mackey; Ainsley J Newson; Jane Nielsen; Jennifer K Wagner; Rebekah E McWhirter
Journal:  Genome Med       Date:  2017-09-25       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.